Eli Lilly : LLY

All Eli Lilly Articles

618 Articles

Jon C. Ogg | May 31, 2014 at 9:06 AM EDT

The Highest-Yielding Dividends That Are Safe to Hold

ThinkstockDividend payments by S&P 500 companies reached an all-time high last year, totaling some $330.8 billion, according to FactSet. As…

cgblaine22 | Apr 26, 2014 at 8:30 AM EDT

Biotech: The Poster Child for Market Volatility in 2014

The NYSE Arca Biotechnology Index fell nearly 9% between a peak on Jan. 22 and a low on Feb. 5.…

Trey Thoelcke | Apr 24, 2014 at 10:55 AM EDT

UPS Joins Others Down in the Dumps

UPS reported first-quarter 2014 results before markets opened Thursday, and no surprise, winter weather was its theme of the day.…

Trey Thoelcke | Apr 24, 2014 at 7:00 AM EDT

Expired Patents Take a Bite out of Eli Lilly Results

Eli Lilly reported disappointing first-quarter 2014 results before markets opened Thursday, due in part to the impact of U.S. patent…

Jon C. Ogg | Apr 3, 2014 at 8:40 AM EDT

Top Analyst Upgrades and Downgrades: Apple, Intel, Chevron, Exxon, Qualcomm, Citigroup and More

These are the top analyst upgrades, downgrades and initiations seen from Wall Street research firms on Thursday, April 3, 2014.…

Trey Thoelcke | Mar 13, 2014 at 8:45 AM EDT

Piper Jaffray Stocks to Buy for S&P 500 Going to 2,100

The chief strategist at Piper Jaffray released his report for March. It details how the second and third quarters typically…

Trey Thoelcke | Mar 10, 2014 at 9:05 AM EDT

Four Upcoming Catalysts That Could Move Pharmaceutical Stocks

In a new research report, Cowen analysts posted a list of some of the top new datapoints cited at the…

Trey Thoelcke | Mar 4, 2014 at 8:50 AM EST

Merrill Lynch’s Top Health Care Stocks to Buy Now

Merrill Lynch likes the health care sector and has made no secret that they think that it can continue to…

Trey Thoelcke | Feb 26, 2014 at 8:25 AM EST

Six New Stocks to Buy in the Piper Jaffray Model Portfolio

Most Wall Street firms run model portfolios for their institutional and retail clients. Here are stocks that recently were added…

Trey Thoelcke | Feb 17, 2014 at 7:05 AM EST

Biotech Buyout Bolsters Novartis Cancer Portfolio

Novartis announced Monday morning that it will acquire privately held startup biotech CoStim Pharmaceuticals. Terms of the deal were not…

Jon C. Ogg | Feb 13, 2014 at 10:40 AM EST

Top Pharma and Biotech Stocks to Buy From Key Investor Conference

With top biotechnology and health care companies from around the world attending the Leerink Global Healthcare, it is a good…

Jon C. Ogg | Jan 23, 2014 at 10:25 AM EST

Ariad Joins Rumor Mill: Hope May Trump Reality

Ariad Pharmaceuticals could be joining the ranks of the next big biotech acquisitions. The company fits the bill of many…

Trey Thoelcke | Dec 18, 2013 at 7:00 AM EST

Teva Secures Rights to Launch Generic Viagra

ThinkstockPfizer Inc.’s (NYSE: PFE) patent protecting popular erectile dysfunction drug Viagra from generic competition may not expire until April 2020,…

Jon C. Ogg | Nov 11, 2013 at 8:45 AM EST

Top Analyst Upgrades and Downgrades: Twitter, Best Buy, Exxon and More

Jon OggNow that we are mostly through earnings season and now that stocks have challenged all-time highs recently, investors and…

Jon C. Ogg | Nov 7, 2013 at 9:15 AM EST

Stocks to Sell or Short: The Seven Least Preferred Stocks at UBS

courtesy Deere & Co.UBS has a list of stocks that investors may want to consider selling. They could even be…

1 … 31 32 33 34 35 … 42

Eli Lilly : LLY

All Eli Lilly Articles

The Highest-Yielding Dividends That Are Safe to Hold

Biotech: The Poster Child for Market Volatility in 2014

UPS Joins Others Down in the Dumps

Expired Patents Take a Bite out of Eli Lilly Results

Top Analyst Upgrades and Downgrades: Apple, Intel, Chevron, Exxon, Qualcomm, Citigroup and More

Piper Jaffray Stocks to Buy for S&P 500 Going to 2,100

Four Upcoming Catalysts That Could Move Pharmaceutical Stocks

Merrill Lynch’s Top Health Care Stocks to Buy Now

Six New Stocks to Buy in the Piper Jaffray Model Portfolio

Biotech Buyout Bolsters Novartis Cancer Portfolio

Top Pharma and Biotech Stocks to Buy From Key Investor Conference

Ariad Joins Rumor Mill: Hope May Trump Reality

Teva Secures Rights to Launch Generic Viagra

Top Analyst Upgrades and Downgrades: Twitter, Best Buy, Exxon and More

Stocks to Sell or Short: The Seven Least Preferred Stocks at UBS

XRP Price Prediction: 3 AI Models Predict Where XRP Will Trade by December 2026

QDVO’s 32% Return Masks a Hidden Risk for Income Investors

Half of America Still Feels Financially Exposed Despite 8% Jump in Security

Half of America Still Feels Financially Exposed Despite 8% Jump in Security

52% of Americans Are Building Wealth While Ignoring Their Greatest Risk

XRP Price Prediction: 3 AI Models Predict Where XRP Will Trade by December 2026

QDVO’s 32% Return Masks a Hidden Risk for Income Investors

Eli Lilly : LLY

All Eli Lilly Articles

The Highest-Yielding Dividends That Are Safe to Hold

Biotech: The Poster Child for Market Volatility in 2014

UPS Joins Others Down in the Dumps

Expired Patents Take a Bite out of Eli Lilly Results

Top Analyst Upgrades and Downgrades: Apple, Intel, Chevron, Exxon, Qualcomm, Citigroup and More

Piper Jaffray Stocks to Buy for S&P 500 Going to 2,100

Four Upcoming Catalysts That Could Move Pharmaceutical Stocks

Merrill Lynch’s Top Health Care Stocks to Buy Now

Six New Stocks to Buy in the Piper Jaffray Model Portfolio

Biotech Buyout Bolsters Novartis Cancer Portfolio

Top Pharma and Biotech Stocks to Buy From Key Investor Conference

Ariad Joins Rumor Mill: Hope May Trump Reality

Teva Secures Rights to Launch Generic Viagra

Top Analyst Upgrades and Downgrades: Twitter, Best Buy, Exxon and More

Stocks to Sell or Short: The Seven Least Preferred Stocks at UBS

XRP Price Prediction: 3 AI Models Predict Where XRP Will Trade by December 2026

QDVO’s 32% Return Masks a Hidden Risk for Income Investors

Half of America Still Feels Financially Exposed Despite 8% Jump in Security

Featured Reads

Half of America Still Feels Financially Exposed Despite 8% Jump in Security

52% of Americans Are Building Wealth While Ignoring Their Greatest Risk